Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arvinas, Inc.    ARVN

ARVINAS, INC.

(ARVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2020 09/23/2020 09/24/2020 09/25/2020 09/28/2020 Date
26.18(c) 24.55(c) 23.89(c) 24.42(c) 22.99(c) Last
267 415 459 418 437 056 335 145 483 784 Volume
-4.10% -6.23% -2.69% +2.22% -5.86% Change
More quotes
Financials (USD)
Sales 2020 22,4 M - -
Net income 2020 -101 M - -
Net cash position 2020 219 M - -
P/E ratio 2020 -9,43x
Yield 2020 -
Sales 2021 22,5 M - -
Net income 2021 -123 M - -
Net cash position 2021 305 M - -
P/E ratio 2021 -8,41x
Yield 2021 -
Capitalization 958 M 958 M -
EV / Sales 2020 33,0x
EV / Sales 2021 29,1x
Nbr of Employees 133
Free-Float 85,4%
More Financials
Company
Arvinas, Inc., formerly Arvinas Holding Co LLC, is a development staged biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to degrade disease-causing proteins. The Company uses its technology platform to engineer proteolysis targeting chimeras (PROTACs), which are designed to harness the body’s own natural protein disposal system to selectively and efficiently... 
Sector
Pharmaceuticals
Calendar
11/09Earnings Release
More about the company
Notations Surperformance© of Arvinas, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ARVINAS, INC.
09/04Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
GL
08/07Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
GL
08/04ARVINAS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/04ARVINAS, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
08/04Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate ..
GL
07/06ARVINAS : Corporate Presentation - July, 2020
PU
06/30ARVINAS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/29Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
GL
06/17Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Health..
GL
06/11ARVINAS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/11Arvinas Appoints Linda Bain to its Board of Directors
GL
06/05ARVINAS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/05Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthca..
GL
06/04ARVINAS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/29ARVINAS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and..
AQ
More news
News in other languages on ARVINAS, INC.
07/24BB Biotech im zweiten Quartal mit Milliardengewinn dank Biotech-Hype
2019Hausdurchsuchungen bei Vitol und Trafigura wegen Petrobras-Skandal
2019Bayer kooperiert mit US-Biotechfirma im Pharma- und Agrargeschäft
2019Bayer s'allie à la biotech américaine Arvinas pour 750 millions de dollars
More news
Chart ARVINAS, INC.
Duration : Period :
Arvinas, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARVINAS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 61,50 $
Last Close Price 24,42 $
Spread / Highest target 224%
Spread / Average Target 152%
Spread / Lowest Target 76,1%
EPS Revisions
Managers
NameTitle
John G. Houston President, Chief Executive Officer & Director
Timothy M. Shannon Chairman
Sean A. Cassidy Chief Financial Officer & Treasurer
Ian Taylor Chief Scientific Officer
Kimberly Wehger Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ARVINAS, INC.-40.57%958
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-7.99%200 326
NOVARTIS AG-12.61%190 402